22nd Century Group, Inc. (XXII): Price and Financial Metrics


22nd Century Group, Inc. (XXII): $1.14

0.02 (+1.79%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add XXII to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

XXII POWR Grades

  • XXII scores best on the Growth dimension, with a Growth rank ahead of 64.13% of US stocks.
  • XXII's strongest trending metric is Quality; it's been moving down over the last 178 days.
  • XXII's current lowest rank is in the Quality metric (where it is better than 0.21% of US stocks).

XXII Stock Summary

  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.17 for 22ND CENTURY GROUP INC; that's greater than it is for just 12.17% of US stocks.
  • With a year-over-year growth in debt of 278.44%, 22ND CENTURY GROUP INC's debt growth rate surpasses 94.33% of about US stocks.
  • Revenue growth over the past 12 months for 22ND CENTURY GROUP INC comes in at 67.89%, a number that bests 87.26% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to XXII, based on their financial statements, market capitalization, and price volatility, are CXDO, SVFD, MLSS, APYX, and FTFT.
  • XXII's SEC filings can be seen here. And to visit 22ND CENTURY GROUP INC's official web site, go to www.xxiicentury.com.

XXII Valuation Summary

  • XXII's price/sales ratio is 5; this is 4.17% higher than that of the median Healthcare stock.
  • XXII's price/sales ratio has moved NA NA over the prior 144 months.

Below are key valuation metrics over time for XXII.

Stock Date P/S P/B P/E EV/EBIT
XXII 2022-11-25 5.0 2.1 -5.4 -5.2
XXII 2022-11-23 5.0 2.1 -5.4 -5.3
XXII 2022-11-22 5.0 2.1 -5.4 -5.3
XXII 2022-11-21 4.5 1.9 -4.8 -4.7
XXII 2022-11-18 5.2 2.2 -5.6 -5.5
XXII 2022-11-17 5.5 2.3 -5.9 -5.7

XXII Growth Metrics

    The 3 year price growth rate now stands at -18.1%.
  • The year over year price growth rate now stands at -57.21%.
  • The year over year revenue growth rate now stands at 19.12%.
XXII's revenue has moved up $27,362,527 over the prior 52 months.

The table below shows XXII's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 50.865 -37.28 -47.483
2022-06-30 39.293 -30.321 -43.821
2022-03-31 33.187 -26.856 -36.497
2021-12-31 30.948 -22.839 -32.609
2021-09-30 30.296 -21.204 -25.048
2021-06-30 29.795 -16.418 -19.829

XXII's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • XXII has a Quality Grade of F, ranking ahead of 0.97% of graded US stocks.
  • XXII's asset turnover comes in at 0.448 -- ranking 5th of 5 Tobacco Products stocks.
  • MO, TPB, and PM are the stocks whose asset turnover ratios are most correlated with XXII.

The table below shows XXII's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.448 0.073 -0.387
2021-03-31 0.485 0.065 -0.480
2020-12-31 0.479 0.051 -0.435
2020-09-30 0.446 0.038 -0.388
2020-06-30 0.425 0.025 -0.494
2020-03-31 0.400 0.015 -0.537

XXII Price Target

For more insight on analysts targets of XXII, see our XXII price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $6.33 Average Broker Recommendation 1.5 (Moderate Buy)

XXII Stock Price Chart Interactive Chart >

Price chart for XXII

XXII Price/Volume Stats

Current price $1.14 52-week high $3.52
Prev. close $1.12 52-week low $0.85
Day low $1.08 Volume 672,400
Day high $1.14 Avg. volume 2,034,670
50-day MA $1.13 Dividend yield N/A
200-day MA $1.72 Market Cap 245.44M

22nd Century Group, Inc. (XXII) Company Bio


22nd Century Group, Inc., a plant biotechnology company, provides technology that allows for the level of nicotine and other nicotinic alkaloids in tobacco plants to be decreased or increased through genetic engineering and plant breeding. The company was founded in 1998 and is based in Clarence, New York.


XXII Latest News Stream


Event/Time News Detail
Loading, please wait...

XXII Latest Social Stream


Loading social stream, please wait...

View Full XXII Social Stream

Latest XXII News From Around the Web

Below are the latest news stories about 22ND CENTURY GROUP INC that investors may wish to consider to help them evaluate XXII as an investment opportunity.

22nd Century Group Provides Update on Incident at Grass Valley Facility

Established backup plans implemented to ensure continuous customer delivery Buffalo, New York--(Newsfile Corp. - November 21, 2022) - GVB Biopharma, a 22nd Century Group company (NASDAQ: XXII), today announced that a fire occurred at its GVB Biopharma distillate and isolate manufacturing facility located in Grass Valley, Oregon, on November 20, 2022. There were no reported life threatening injuries, but the fire damaged the facility."We want to thank the first responders who were able ...

Yahoo | November 21, 2022

22nd Century Group had a big year. The FDA could make 2023 even bigger.

A big acquisition and a major product launch contributed to 22nd Century Group's third-quarter earnings growth of 148% year over year. Next year, could be even bigger, thanks to FDA changes.

Yahoo | November 17, 2022

22nd Century Group’s GVB Biopharma Opens New Central Distribution Facility in The Netherlands

New distribution facility supports rapidly growing demand for hemp/cannabis productsBUFFALO, N.Y., Nov. 16, 2022 (GLOBE NEWSWIRE) -- GVB Biopharma, a 22nd Century Group company (Nasdaq: XXII), today announced that it has opened a new, strategically-located distribution facility in the Netherlands to support its growing business in Europe, the Middle East, and Africa (EMEA). The new distribution facility will increase existing and new customer access to GVB’s quality hemp/cannabis products, speed

Yahoo | November 16, 2022

22nd Century Group (Nasdaq: XXII) GVB Biopharma to Exhibit at MJBizCon in Las Vegas

BUFFALO, N.Y., Nov. 15, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, today announced that the Company’s GVB Biopharma business will attend and be an exhibitor at MJBizCon in Las Vegas on November 16 to 18, 2022. “We’re excited to be exhibiting at MJBizCon for the fourth year, and this time with the combined GVB and 22n

Yahoo | November 15, 2022

22nd Century Group (Nasdaq: XXII) to Participate in November 2022 Investor Conferences

BUFFALO, N.Y., Nov. 14, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, today announced that the Company will be participating in the following investor conferences: On Tuesday, November 15, 2022, the Company will host one-on-one meetings at the Roth 2nd Annual AgTech Answers Event.On Thursday, November 17, 2022, the Comp

Yahoo | November 14, 2022

Read More 'XXII' Stories Here

XXII Price Returns

1-mo -14.29%
3-mo -14.93%
6-mo -42.42%
1-year -55.47%
3-year 10.68%
5-year -51.07%
YTD -63.11%
2021 40.45%
2020 100.00%
2019 -55.82%
2018 -11.07%
2017 156.88%

Continue Researching XXII

Here are a few links from around the web to help you further your research on 22nd Century Group Inc's stock as an investment opportunity:

22nd Century Group Inc (XXII) Stock Price | Nasdaq
22nd Century Group Inc (XXII) Stock Quote, History and News - Yahoo Finance
22nd Century Group Inc (XXII) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7401 seconds.